Developer docs
API playgroundTry for free, no card

Search company profiles

PaxMedica

Full company profile

uuid0002vtg

Namestring
PaxMedica
Websiteurl
paxmedica.com
Company typeenum
Public
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTarrytown, United States
HQ citystring
Tarrytown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical-stage biopharmaceuticals, autism spectrum disorder therapy, neurodevelopmental disorder drugs, neurological disorder treatment, drug development pipeline
Industry1 code
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage biopharmaceutical drug development
No data
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PaxMedica is a clinical-stage biopharmaceutical company developing drug therapies for neurodevelopmental and neurological disorders, with its primary drug candidate PAX-101 being advanced through clinical development. The company is pursuing manufacturing validation and NDA submission for PAX-101 to treat autism spectrum disorder (ASD) and other neurological conditions.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1PAX-101
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeDirect peer
Description

CNS-focused biopharmaceutical company developing and commercializing therapies for neurological and psychiatric conditions; comparable in therapeutic focus and stage of CNS drug development to PaxMedica.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing cannabinoid-based transdermal therapies for Fragile X syndrome and autism spectrum disorder—a near-direct comparator to PaxMedica's PAX-101 in neurodevelopmental disorders.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing therapeutics for seizure disorders and other neurological conditions; comparable as a small-cap CNS drug developer at similar stage.

TypeBroad incumbent
Description

Established biopharmaceutical company commercializing CNS therapies (e.g., Rett syndrome, Parkinson's psychosis); comparable CNS/neuro focus but with commercial-stage assets.

TypeBroad incumbent
Description

Established RNA-targeted therapeutics company with a significant neurological disease pipeline; comparable CNS/neurodegenerative development focus.

TypeBroad incumbent
Description

Biopharmaceutical company developing therapeutics for neurodegenerative diseases; comparable CNS/neurodegenerative focus though at a larger scale and broader modality footprint.

TypeDirect peer
Description

CNS-focused biopharmaceutical company developing therapies for neuropsychiatric conditions; comparable as a clinical-to-commercial-stage CNS innovator pharma.

TypeBroad incumbent
Description

Established biopharmaceutical company developing treatments for rare diseases including neurological conditions; comparable neuro/rare-disease focus but at commercial scale.

TypeDirect peer
Description

Biopharmaceutical company developing CNS therapies for disorders including epilepsy and depression; directly comparable as a small-to-mid cap CNS-focused innovator pharma.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on monogenic CNS diseases; comparable as a small-cap neurology-focused biotech pursuing rare neurodevelopmental indications.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PaxMedica

Clinical-stage biopharmaceutical drug developmentpaxmedica.com

PaxMedica firmographics

Firmographics
Name
PaxMedica
Website
https://paxmedica.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

PaxMedica industry classification

Industry
Product category
Clinical-stage biopharmaceutical drug development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceuticals
  • Autism spectrum disorder therapy
  • Neurodevelopmental disorder drugs
  • Neurological disorder treatment
  • Drug development pipeline

Where PaxMedica is headquartered

Location

Headquarters

HQ city
Tarrytown
HQ country
United States
HQ region
North America

Markets served

PaxMedica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

PaxMedica product offering

Product offering

Core offering

PaxMedica is a clinical-stage biopharmaceutical company developing drug therapies for neurodevelopmental and neurological disorders, with its primary drug candidate PAX-101 being advanced through clinical development. The company is pursuing manufacturing validation and NDA submission for PAX-101 to treat autism spectrum disorder (ASD) and other neurological conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • PAX-101

Companies that use PaxMedica

Customer profile

Segments1 record

Ideal customer profiles1 record

PaxMedica technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

PaxMedica partnerships and signals

Strategic signal

Scale indicators3 records

PaxMedica competitors and assessment

Company assessment

Direct peers

  • Axsome Therapeutics: CNS-focused biopharmaceutical company developing and commercializing therapies for neurological and psychiatric conditions; comparable in therapeutic focus and stage of CNS drug development to PaxMedica.
  • Zynerba Pharmaceuticals: Clinical-stage biopharmaceutical company developing cannabinoid-based transdermal therapies for Fragile X syndrome and autism spectrum disorder—a near-direct comparator to PaxMedica's PAX-101 in neurodevelopmental disorders.
  • Marinus Pharmaceuticals: Clinical-stage biopharmaceutical company developing therapeutics for seizure disorders and other neurological conditions; comparable as a small-cap CNS drug developer at similar stage.
  • Karuna Therapeutics: CNS-focused biopharmaceutical company developing therapies for neuropsychiatric conditions; comparable as a clinical-to-commercial-stage CNS innovator pharma.
  • Sage Therapeutics: Biopharmaceutical company developing CNS therapies for disorders including epilepsy and depression; directly comparable as a small-to-mid cap CNS-focused innovator pharma.
  • Taysha Gene Therapies: Clinical-stage gene therapy company focused on monogenic CNS diseases; comparable as a small-cap neurology-focused biotech pursuing rare neurodevelopmental indications.

Broad incumbents

  • Acadia Pharmaceuticals: Established biopharmaceutical company commercializing CNS therapies (e.g., Rett syndrome, Parkinson's psychosis); comparable CNS/neuro focus but with commercial-stage assets.
  • Ionis Pharmaceuticals: Established RNA-targeted therapeutics company with a significant neurological disease pipeline; comparable CNS/neurodegenerative development focus.
  • Denali Therapeutics: Biopharmaceutical company developing therapeutics for neurodegenerative diseases; comparable CNS/neurodegenerative focus though at a larger scale and broader modality footprint.
  • BioMarin Pharmaceutical: Established biopharmaceutical company developing treatments for rare diseases including neurological conditions; comparable neuro/rare-disease focus but at commercial scale.

Market position

Customer concentration

PaxMedica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PaxMedica leadership team

Management profile

Number of profiles

Profiles2 records

PaxMedica funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PaxMedica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PaxMedica

What does PaxMedica do?

PaxMedica is a clinical-stage biopharmaceutical company developing drug therapies for neurodevelopmental and neurological disorders, with its primary drug candidate PAX-101 being advanced through clinical development. The company is pursuing manufacturing validation and NDA submission for PAX-101 to treat autism spectrum disorder (ASD) and other neurological conditions.

Is PaxMedica a public or private company?

PaxMedica is a public company. It is classified as public and is currently operating.

When was PaxMedica founded?

PaxMedica was founded in 2018. It employs 1 to 10 people.

Where is PaxMedica based?

PaxMedica is headquartered in Tarrytown, United States, in the North America region.

Who are PaxMedica's main competitors?

Direct peers on record are Axsome Therapeutics, Zynerba Pharmaceuticals, Marinus Pharmaceuticals, Karuna Therapeutics, Sage Therapeutics and Taysha Gene Therapies. Broad incumbents are Acadia Pharmaceuticals, Ionis Pharmaceuticals, Denali Therapeutics and BioMarin Pharmaceutical.

Does PaxMedica have an API?

No public API is recorded for PaxMedica.

What industry is PaxMedica in?

PaxMedica's product category is Clinical-stage biopharmaceutical drug development. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ticker ReportPaxMedica (PXMD) Expected to Release Earnings on WednesdayPaxMedica, a clinical-stage biopharmaceutical company based in Burlingame, California, is expected to report earnings on Wednesday, September 2nd. Analysts anticipate a loss of $0.88 per share for the quarter. The company's lead program centers on arbaclofen, a proprietary formulation targeting social functioning in autism spectrum disorders.AD HOC NEWSStrategic Execution in Focus for Paxmedica InvestorsPaxmedica is facing a volatile biotech sector environment in March 2026, with its stock performance depending heavily on clinical progress, regulatory navigation, and operational milestone execution. Market observers note that the company must balance cash reserve management with strategic R&D prioritization while navigating FDA approval patterns and sector-wide regulatory scrutiny. The company's forthcoming updates on project progress are expected to set near-term direction as investors weigh its strategic choices against broader industry uncertainty.Business & FinancialBiomednewsbreaks Paxmedica Inc. (NASDAQ: PXMD) Provides Update On Its Response To Extraordinary Request To Provide PAX-101 To MalawiPaxMedica announced the first patient with Human Africa Trypanosomiasis Brucei Rhodesiense in Malawi was treated with PAX-101, an intravenous Suramin formulation. The patient is recovering at home, and the company said it will continue supplying Suramin to Malawi and other East African countries.Business & FinancialBiomednewsbreaks - Paxmedica Inc. (PXMD) Committed To Global Health, Potential Positive Impact Of PAX-101PaxMedica is preparing to submit a New Drug Application for suramin to treat Human African Trypanosomiasis, following an emergency release to Malawi in April 2024. The company will hold a Type C meeting with the FDA for PAX-101, an intravenous suramin formulation for autism and HAT, which could advance clinical trials and approval.GlobeNewswirePaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell PodcastPaxMedica CEO Howard Weisman and Malawi health official Dr. Marshal Lemerani discussed the urgent need for IV suramin (PAX-101) to treat sleeping sickness in Malawi on the Bell2Bell Podcast. The company highlighted its commitment to addressing the critical shortage of this medication for Trypanosoma brucei rhodesiense.GlobeNewswirePaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101PaxMedica Inc. said it will provide immediate access to its PAX-101 (IV suramin) to Malawi's Ministry of Health within 30 days, responding to an urgent request for the drug to combat sleeping sickness. The company has completed three registration batches of PAX-101 and plans to submit a new NDA for the treatment of TBr HAT.BenzingaWhy JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday’s Mid-Day SessJPMorgan Chase & Co. reported first-quarter earnings with managed net revenue of $42.5 billion, up 8% year-over-year, beating the consensus estimate of $41.8 billion, while EPS of $4.44 also exceeded the $4.15 consensus estimate; however, shares fell 5.1% to $185.49 during Friday's session. Benzinga's mid-day movers compilation highlights multiple stocks with significant price swings, including PaxMedica surging 143% after completing pivotal registration batches and Motus GI dropping 39.7% amid Nasdaq delisting concerns.BenzingaPenny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application SubPaxMedica Inc completed the execution of three pivotal registration/validation batches of PAX-101, an IV formulation of suramin for treating Stage 1 Human African Trypanosomiasis, marking an essential milestone toward an NDA submission to the FDA planned for Q4 2024. A successful NDA review and approval could enable commercial availability of the first and only form of suramin for this fatal neglected tropical disease in the United States, and potentially qualify the company for a Tropical Disease Priority Review Voucher. The company also plans to advance research of PAX-101 as a treatment for Autism Spectrum Disorder.BenzingaCitigroup, JPMorgan And 3 Stocks To Watch Heading Into Friday - Citigroup (NYSE:C), JPMorgan Chase (NYSE:U.S. stock futures traded slightly higher on Friday ahead of quarterly earnings reports from major banks, with analysts expecting Citigroup to report earnings of $1.20 per share on revenue of $20.39 billion and JPMorgan Chase to post earnings of $4.15 per share on revenue of $41.84 billion. Argan, Inc. reported better-than-expected fourth-quarter results, sending its shares surging 7.4%, while PaxMedica announced the completed execution of three pivotal registration batches for PAX-101, causing its shares to jump 116.1% in after-hours trading.